Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PLA2G7 | Q13093 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26968681 | 0.87 | LMNA (0.54) | ELANES1PR4MEN1HPGDKMT2A | |
| SCHEMBL197716 | 0.87 | ALDH1A1 (0.52) | ELANES1PR4ALOX15MEN1HPGD | |
| SCHEMBL11729295 | 0.85 | ELANE (0.52) | ELANEALOX15MEN1HPGDKMT2A | |
| SCHEMBL29590360 | 0.85 | ELANE (0.52) | ELANEALOX15MEN1HPGDKMT2A | |
| SCHEMBL732604 | 0.84 | S1PR4 (0.47) | ELANES1PR4ALOX15MEN1HPGD | |
| SCHEMBL10385111 | 0.82 | HPGD (0.51) | ELANES1PR4ALOX15MEN1HPGD | |
| SCHEMBL852186 | 0.82 | MAOB (0.49) | ELANES1PR4ALOX15MEN1HPGD | |
| SCHEMBL7587489 | 0.82 | HDAC7 (0.46) | ELANES1PR4MEN1HPGDKMT2A | |
| SCHEMBL851675 | 0.82 | ELANE (0.45) | ELANES1PR4ALOX15MEN1HPGD | |
| SCHEMBL15430420 | 0.82 | HPGD (0.59) | ELANEALOX15MEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127217-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-15 | — | — | US | disclosed |
| EP-2797862-B1 | OLEFIN OLIGOMERIZATION METHODS | CHEVRON PHILLIPS CHEMICAL CO LP (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2021-01-28 | — | — | US | disclosed |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3507269-B1 | STABLE HYDROFORMYLATION CATALYST FOR PREPARATION OF HIGH N/ISO RATIO ALDEHYDE PRODUCT | EASTMAN CHEM CO (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200290966-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2020-05-28 | — | — | US | disclosed |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-10570092-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| WO-1995017471-A1 | DISAZO COMPOUND | ZENECA LIMITED (GB) | 1995-06-29 | — | — | WO | disclosed |
| US-5069991-A | NAPHTHOLACTAM OR ISINDOLENINE DYE | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-03 | — | — | US | disclosed |
| EP-0289122-B1 | UNSATURATED DERIVATIVES OF METHYLENE DIANILINE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-11-27 | — | — | EP | disclosed |
| US-4922020-A | 1,1,5,5-tetra(4-aminophenyl)-pentadi-1,4-ene compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-01 | — | — | US | disclosed |
| US-4906541-A | Electrophotographic recording element containing a naphtholactam dye sensitizer | BASF AKTIENGESELLSCHAFT (DE) | 1990-03-06 | — | — | US | disclosed |
| EP-0187520-B1 | WATER-SOLUBLE DYE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-01-24 | — | — | EP | disclosed |
| EP-0289122-A1 | Unsaturated derivatives of methylene dianiline | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-11-02 | — | — | EP | disclosed |
| US-4777248-A | Water-soluble non-reactive triazinyl mono-azo dye for ink jet printing | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-10-11 | — | — | US | disclosed |
| US-4726844-A | LIGHTFASTNESS | CANON KABUSHIKI KAISHA (JP) | 1988-02-23 | — | — | US | disclosed |
| EP-0187520-A2 | Water-soluble dye | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | ELANE 4700/4885S1PR4 448/4885ALOX15 3826/4885 |
| US-11247969-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | ELANE 3708/4885S1PR4 632/4885ALOX15 3323/4885 |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | ELANE 3108/4885S1PR4 372/4885ALOX15 2742/4885 |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | ELANE 4696/4885S1PR4 370/4885ALOX15 3712/4885 |
| US-10570092-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | ELANE 3708/4885S1PR4 632/4885ALOX15 3323/4885 |
| US-20200290966-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | ELANE 3708/4885S1PR4 632/4885ALOX15 3323/4885 |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | ELANE 4696/4885S1PR4 370/4885ALOX15 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.